Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Lexaria Bioscience Corp.: Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...
Hydreight Technologies Expands Telehealth Offerings with Launch of NAD+ Therapy on VSDHOne Platform
New NAD+ Patch, Injection, and Nasal Spray Now Available for Personalized Wellness and Longevity SolutionsVANCOUVER, British Columbia and LAS VEGAS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Hydreight ...